{"schema_version":"secwatch.filing_event.v1","accession":"0000882095-25-000041","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.452607+00:00","generated_at":"2026-05-17T04:40:58.986888+00:00","sec_items":["7.01","9.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gilead settles Biktarvy patent litigations; no generic entry expected before April 1, 2036","bullets":["Settlements with Lupin, Cipla, and Laurus Labs resolve patent disputes over generic Biktarvy.","No generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) permitted in US before April 1, 2036.","Agreements are subject to standard acceleration provisions.","Biktarvy is Gilead's leading HIV treatment; extending exclusivity protects significant revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0000882095-25-000041","json":"https://secwatch.observer/filing/0000882095-25-000041.json","markdown":"https://secwatch.observer/filing/0000882095-25-000041.md","text":"https://secwatch.observer/filing/0000882095-25-000041.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000041/0000882095-25-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000088209525000041/gild-20251006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:40:58.986888+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}